- Services & Solutions
- Clients & Partners
Promising Cancer Therapeutics Developed by SRI International
MENLO PARK, Calif. – June 1, 2007 – SRI International, an independent nonprofit research and development organization, announced today the continued progress of several compounds that show promise as therapeutics against cancer. SRI executives will be on hand at the 2007 meeting of the American Society of Clinical Oncology (ASCO) to discuss potential partnerships for further development of these anticancer agents.
"For more than half a century, SRI has conducted basic and applied research in the discovery and development of new drugs. With three drugs on the market, four in various stages of clinical trials and five lead compounds in preclinical development, our success is clearly demonstrated by our pipeline," said Nathan Collins, Ph.D., executive director of Drug Discovery in SRI's Biosciences Division. "Oncology has always been an important focus of our work. We look forward to new partnerships to continue development of SRI’s promising drug candidates."
Recent SRI developments in oncology include:
- Tirapazamine, a Phase III clinical cytotoxic drug candidate for use in combination therapy. Tirapazamine is a first in class bioreductively activated, hypoxia-selective small molecule that targets solid tumors.
- SR16388, a novel antiangiogenic steroid currently in pre-clinical development for the treatment of multiple tumor types including metastatic prostate cancer.
- SR16157, a novel, dual-targeted steroidal sulfatase inhibitor and selective estrogen receptor modulator, for the treatment of advanced breast cancer. The drug is undergoing final IND-directed toxicology testing.
- SR13668, a novel inhibitor of the PI3K/Akt pathway. It is an orally active, small molecule drug that has shown promise for the treatment of a range of advanced and frequently lethal cancers including non-small cell lung cancer and androgen-independent prostate cancer.
SRI is a world leader in the discovery and development of novel treatments for cancer. Through collaborations, grants and contracts with government and commercial clients and partners, SRI identifies new molecular targets, discovers novel lead compounds, develops innovative models for evaluating efficacy, elucidates mechanisms of action, optimizes interesting leads, and develops cost-effective syntheses. SRI’s Biosciences Division is also a leading provider of preclinical services for cancer therapeutics, cancer vaccines, and chemopreventive agents of interest to biotechnology and pharmaceutical companies and the NCI.
About SRI's Biosciences Division
SRI International's Biosciences Division is an organization of approximately 200 people with all of the resources necessary to take biological and chemical research programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials. SRI Biosciences is a unique organization: it conducts basic research like a university, performs drug discovery and develops biologics like a biotechnology company, and is a contract research organization (CRO) that offers a full range of preclinical development and pharmaceutical sciences services. SRI Biosciences specializes in cancer, immunology, infectious disease, and neurosciences research.
To date, SRI has developed nine drugs internally that have entered clinical trials, with several more currently undergoing preclinical evaluation. Marketed examples of these drugs include Targretin® (bexarotene) and Halfan® (halofantrine). Additionally, working with government and industry partners, SRI has helped advance on the order of 100 drugs into clinical trials, and 30 drugs onto the market. Through collaborations with other divisions at SRI, Biosciences is also working at the interfaces of science to create technical platforms for the next generation of drug discovery and development in areas such as drug delivery, devices, diagnostics, and systems biology.
About SRI International
Silicon Valley-based SRI International (www.sri.com) is one of the world’s leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for more than 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.